What Is Across-Group Significance?

Why It Matters for Supplement Brands

Across-group significance is the most important type of statistical result for supplement substantiation. It answers the question: 'Did the supplement group perform significantly better than the placebo group?' This is the standard the FDA, FTC, and regulatory bodies use to evaluate whether an ingredient genuinely works.

How It Works

In a well-designed RCT:

• **Across-group comparison**: Treatment group vs. placebo group at the study endpoint. This is the primary analysis. • **Within-group comparison**: Before vs. after within the same group. This is weaker because improvements could be due to the placebo effect, natural fluctuation, or regression to the mean.

Example: • If the supplement group reduced cortisol by 30% AND the placebo group reduced cortisol by 25%, the within-group change is 30% but the across-group difference is only 5% — which may not be statistically significant. • True efficacy is demonstrated when the across-group p-value is < 0.05.

Nutra Comp distinguishes between across-group and within-group significance in its evidence analysis, highlighting both but prioritising across-group findings for claim generation.

Common Mistakes to Avoid

• ✗Citing within-group improvements as evidence of efficacy without checking the across-group comparison
• ✗Marketing claims based on '30% improvement' when the placebo group also improved by 25%
• ✗Not recognising that within-group significance (p < 0.05 for before/after) can occur even when across-group significance (p > 0.05) shows no real treatment effect
• ✗Failing to request or check the across-group statistical analysis when reviewing a study

Related Terms

See It in Action

Explore how this concept applies to real ingredient substantiation:

Automate Your Substantiation

Nutra Comp turns weeks of manual research into minutes of automated clinical evidence analysis and FDA-compliant claim generation.